Skip to main content
Top
Published in: Tumor Biology 11/2014

01-11-2014 | Research Article

High expression of UCH37 is significantly associated with poor prognosis in human epithelial ovarian cancer

Authors: Lin Wang, Yan-Jie Chen, Kai Xu, Ya-Yun Wang, Xi-Zhong Shen, Rui-Qin Tu

Published in: Tumor Biology | Issue 11/2014

Login to get access

Abstract

Ubiquitin carboxyl-terminal hydrolase 37 (UCH37) is a member of deubiquitinating enzymes. It can suppress protein degradation through disassembling polyubiquitin from the distal subunit of the chain. The aim of this study was to assess the value of UCH37 in predicting tumor recurrence after curative resection in epithelial ovarian cancer (EOC) patients. In this study, the expression level of UCH37 in 5 paired EOC and normal tissue was tested by Western blot. And the association of UCH37 expression and prognostic value was analyzed in 100 tumor specimens from EOC patients, who underwent curative resection between 2003 and 2011. We found that UCH37 was up-regulated in most of the tumor tissue and high expression of UCH37 was an independent significant predictor associated with the poor outcome and recurrence of EOC (p = 0.0037 and p = 0.0042 in overall and disease-free survival, respectively), especially in the advanced stage of EOC (p = 0.0106 and p = 0.0115 in overall and disease-free survival, respectively), and may become a novel predictor for prognosis of EOC patients after curative resection. Our data suggest for the first time that UCH37 overexpression is associated with advanced tumor progression and poor clinical outcome of EOC patients and may help physicians make informed decisions regarding adjuvant treatment following curative resection.
Literature
10.
go back to reference Chen YJ, Ma YS, Fang Y, Wang Y, Fu D, Shen XZ. Power and promise of ubiquitin carboxyl-terminal hydrolase 37 as a target of cancer therapy. Asian Pacific journal of cancer prevention : APJCP. 2013;14(4):2173–9.PubMedCrossRef Chen YJ, Ma YS, Fang Y, Wang Y, Fu D, Shen XZ. Power and promise of ubiquitin carboxyl-terminal hydrolase 37 as a target of cancer therapy. Asian Pacific journal of cancer prevention : APJCP. 2013;14(4):2173–9.PubMedCrossRef
12.
go back to reference Rolen U, Kobzeva V, Gasparjan N, Ovaa H, Winberg G, Kisseljov F, et al. Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog. 2006;45(4):260–9. doi:10.1002/mc.20177.PubMedCrossRef Rolen U, Kobzeva V, Gasparjan N, Ovaa H, Winberg G, Kisseljov F, et al. Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog. 2006;45(4):260–9. doi:10.​1002/​mc.​20177.PubMedCrossRef
14.
15.
go back to reference Fang Y, Fu D, Tang W, Cai Y, Ma D, Wang H, et al. Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19. Biochim Biophys Acta. 2013;1833(3):559–72. doi:10.1016/j.bbamcr.2012.11.020.PubMedCrossRef Fang Y, Fu D, Tang W, Cai Y, Ma D, Wang H, et al. Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19. Biochim Biophys Acta. 2013;1833(3):559–72. doi:10.​1016/​j.​bbamcr.​2012.​11.​020.PubMedCrossRef
17.
go back to reference Wang L, Chen YJ, Hou J, Wang YY, Tang WQ, Shen XZ et al. Expression and clinical significance of BIRC6 in human epithelial ovarian cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014. doi:10.1007/s13277-014-1641-6. Wang L, Chen YJ, Hou J, Wang YY, Tang WQ, Shen XZ et al. Expression and clinical significance of BIRC6 in human epithelial ovarian cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014. doi:10.​1007/​s13277-014-1641-6.
Metadata
Title
High expression of UCH37 is significantly associated with poor prognosis in human epithelial ovarian cancer
Authors
Lin Wang
Yan-Jie Chen
Kai Xu
Ya-Yun Wang
Xi-Zhong Shen
Rui-Qin Tu
Publication date
01-11-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2446-3

Other articles of this Issue 11/2014

Tumor Biology 11/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine